A metabolomic signature of treated and drug-naïve patients with Parkinson's disease: a pilot study.

Jacopo TroisiAnnamaria LandolfiCarmine VitaleKatia LongoAutilia CozzolinoMassimo SquillanteMaria Cristina SavanelliPaolo BaroneMarianna Amboni

Published in: Metabolomics : Official journal of the Metabolomic Society (2019)

Metabolomics can be useful in pathogenetic studies and biomarker discovery. The latter needs large-scale validation and comparison with other neurodegenerative conditions.

Keyphrases

small molecule
mass spectrometry
case control
adverse drug
newly diagnosed